On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for its Clinical Trial Authorization application for a Phase 2/3 study evaluating opaganib (Yeliva, ABC294640)1 in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.

The study was also approved in the UK and a similar application is under review in Italy with plans to further expand the study to additional countries.